Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progenitor Cells Clear all
Completed No phase listed Observational

Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis

NCT01601951
View directory record Official record
Conditions
Hip and Knee Osteoarthritis
Interventions
Procedural, Bone Marrow concentrate injection
Other
Lead sponsor
Regenerative Pain Center, Illinois
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Eltrombopag for Post Transplant Thrombocytopenia

NCT01000051
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

NCT00089453
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Cyclophosphamide, Melphalan, Fludarabine, Bortezomide, Leukapheresis, Interleukin, Infusion #1, Leukapheresis #2, Infusion #2, Auto Graft
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 30, 2026, 6:33 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

NCT05027945
View directory record Official record
Conditions
Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions
Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY)
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 6:33 AM EDT
Not listed Not applicable Interventional

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

NCT00006056
View directory record Official record
Conditions
Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, filgrastim, methotrexate, allogeneic hematopoietic stem cell transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

NCT02993783
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Vedolizumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Not applicable Interventional

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

NCT02326675
View directory record Official record
Conditions
Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions
Ice, Normal Saline Solution
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells

NCT02863029
View directory record Official record
Conditions
Obesity
Interventions
Flexible Sigmoidoscopy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

NCT00539656
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Leukemia, Bilineage, Acute, Leukemia, Myeloid, Chronic
Interventions
Ex vivo expansion of cord blood
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease

NCT00004294
View directory record Official record
Conditions
Gaucher's Disease
Interventions
human glucocerebrosidase gene into autologous peripheral blood stem cells
Genetic
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:33 AM EDT
Recruiting Early Phase 1 Interventional

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

NCT07358195
View directory record Official record
Conditions
Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Interventions
Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant, Hematopoietic Cell Transplantation
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 6:33 AM EDT
Recruiting Not applicable Interventional

Testicular Tissue Cryopreservation for Fertility Preservation

NCT02972801
View directory record Official record
Conditions
Cancer, Autoimmune Disorders
Interventions
Testicular biopsy
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
Male only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

NCT01822509
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • South Pasadena, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Early Phase 1 Interventional

Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery

NCT06280092
View directory record Official record
Conditions
Epilepsy
Interventions
AMSCs
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 1Phase 2 Interventional

Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone

NCT00006234
View directory record Official record
Conditions
Metastatic Cancer, Sarcoma
Interventions
peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 30, 2026, 6:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers

NCT00005907
View directory record Official record
Conditions
Active Immunity, Healthy, Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 2 Interventional

Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

NCT00143871
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
Rituximab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Phase 1 Interventional

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

NCT01630564
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Aldesleukin, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion, Umbilical Cord Blood-Derived Lymphocyte Therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
6 Months and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 30, 2026, 6:33 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction

NCT03678467
View directory record Official record
Conditions
Mandible Tumor, Mandibular Injuries, Mandible; Deformity
Interventions
EB-CMF
Combination Product
Lead sponsor
Epibone, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
San Francisco, California • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 30, 2026, 6:33 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessing Pulmonary Changes in HSCT

NCT07823036
View directory record Official record
Conditions
HSCT, Respiratory, Gas Exchange Impairment
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 6:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

NCT00609739
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia

NCT00643981
View directory record Official record
Conditions
Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis, Coronary Arteriosclerosis
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 30, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Results available

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

NCT03406884
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
c-kit+ cells
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
1 Day to 21 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 6:33 AM EDT